Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Bagnoli, Marina ^a   Beretta, Giovanni L ^a   Gatti, Laura ^a   Pilotti, Silvana ^a   Alberti, Paola ^a   Tarantino, Eva ^a   Barbareschi, Mattia ^b   Canevari, Silvana ^a   Mezzanzanica, Delia ^a   Perego, Paola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; ABCC4 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; TUMOR MARKER; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PROTEIN EXPRESSION; TISSUE MICROARRAY; BIOSYNTHESIS; CANCER STAGING; CARCINOMA; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884234071     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/143202     Document Type: Article

References (22)

1. Guarneri V., Piacentini F., Barbieri E., Conte P. F., Achievements and unmet needs in the management of advanced ovarian cancer. Gynecologic Oncology 2010 117 2 152 158 2-s2.0-77950188167 10.1016/j.ygyno.2009.11.033
2. Vaughan S., Coward J. I., Bast R. C. Jr., Berchuck A., Berek J. S., Brenton J. D., Coukos G., Crum C. C., Drapkin R., Etemadmoghadam D., Friedlander M., Gabra H., Kaye S. B., Lord C. J., Lengyel E., Levine D. A., McNeish I. A., Menon U., Mills G. B., Nephew K. P., Oza A. M., Sood A. K., Stronach E. A., Walczak H., Bowtell D. D., Balkwill F. R., Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer 2011 11 10 719 725 2-s2.0-80053168788 10.1038/nrc3144
3. Bast R. C. Jr., Hennessy B., Mills G. B., The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer 2009 9 6 415 428 2-s2.0-67649440886
4. Muggia F., Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecologic Oncology 2009 112 1 275 281 2-s2.0-57649101120 10.1016/j.ygyno.2008.09.034
5. Gillet J.-P., Efferth T., Remacle J., Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochimica et Biophysica Acta 2007 1775 2 237 262 2-s2.0-34250219965 10.1016/j.bbcan.2007.05.002
6. Gottesman M. M., Fojo T., Bates S. E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2002 2 1 48 58 2-s2.0-0036364467
7. Borst P., Evers R., Kool M., Wijnholds J., A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute 2000 92 16 1295 1302 2-s2.0-0034674901
8. Fletcher J. I., Haber M., Henderson M. J., Norris M. D., ABC transporters in cancer: more than just drug efflux pumps. Nature Reviews Cancer 2010 10 2 147 156 2-s2.0-75149143363 10.1038/nrc2789
9. Beretta G. L., Benedetti V., Cossa G., Assaraf Y. G. A., Bram E., Gatti L., Corna E., Carenini N., Colangelo D., Howell S. B., Zunino F., Perego P., Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochemical Pharmacology 2010 79 8 1108 1117 2-s2.0-77249107728 10.1016/j.bcp.2009.12.002
10. Leonard G. D., Fojo T., Bates S. E., The role of ABC transporters in clinical practice. Oncologist 2003 8 5 411 424 2-s2.0-0141888537 10.1634/theoncologist.8-5-411
11. Sassi Y., Hara Y., Lompré A.-M., Hulot J.-S., Multi-drug resistance protein 4 (MRP4/ABCC4) and cyclic nucleotides signaling pathways. Cell Cycle 2009 8 7 962 963 2-s2.0-65949099107
12. Aldovini D., Demichelis F., Doglioni C., Di Vizio D., Galligioni E., Brugnara S., Zeni B., Griso C., Pegoraro C., Zannoni M., Gariboldi M., Balladore E., Mezzanzanica D., Canevari S., Barbareschi M., M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. International Journal of Cancer 2006 119 8 1920 1926 2-s2.0-33748495333 10.1002/ijc.22082
13. Berman M. L., Future directions in the surgical management of ovarian cancer. Gynecologic Oncology 2003 90 2 S33 S39 2-s2.0-17344384997
14. Miller A. B., Hoogstraten B., Staquet M., Winkler A., Reporting results of cancer treatment. Cancer 1981 47 1 207 214 2-s2.0-0019365237
15. + cells display stem-like features and are spared by cisplatin treatment. Proceedings of the National Academy of Sciences of the United States of America 2009 106 38 16281 16286 2-s2.0-70349479538 10.1073/pnas.0905653106
16. Aguilar-Mahecha A., Hassan S., Ferrario C., Basik M., Microarrays as validation strategies in clinical samples: tissue and protein microarrays. OMICS 2006 10 3 311 326 2-s2.0-33750937356 10.1089/omi.2006.10.311
17. Norris M. D., Smith J., Tanabe K., Tobin P., Flemming C., Scheffer G. L., Wielinga P., Cohn S. L., London W. B., Marshall G. M., Allen J. D., Haber M., Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Molecular Cancer Therapeutics 2005 4 4 547 553 2-s2.0-18044375868 10.1158/1535-7163.MCT-04-0161
18. Haber M., Smith J., Bordow S. B., Flemming C., Cohn S. L., London W. B., Marshall G. M., Norris M. D., Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. Journal of Clinical Oncology 2006 24 10 1546 1553 2-s2.0-33645747683 10.1200/JCO.2005.01.6196
19. Harter P., Hilpert F., Mahner S., Heitz F., Pfisterer J., Bois A. D., Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Review of Anticancer Therapy 2010 10 1 81 88 2-s2.0-74749089537 10.1586/ERA.09.165
20. Faggad A., Darb-Esfahani S., Wirtz R., Sinn B., Sehouli J., Könsgen D., Lage H., Noske A., Weichert W., Buckendahl A.-C., Budczies J., Müller B. M., Elwali N. E., Dietel M., Denkert C., Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis. Histopathology 2009 54 6 657 666 2-s2.0-65349104785 10.1111/j.1365-2559.2009.03297.x
21. Vander Borght S., Komuta M., Libbrecht L., Katoonizadeh A., Aerts R., Dymarkowski S., Verslype C., Nevens F., Roskams T., Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver International 2008 28 10 1370 1380 2-s2.0-54049149978 10.1111/j.1478-3231. 2008.01889.x
22. Gatti L., Beretta G. L., Cossa G., Zunino F., Perego P., ABC transporters as potential targets for modulation of drug resistance. Mini-Reviews in Medicinal Chemistry 2009 9 9 1102 1112 2-s2.0-70349572622 10.2174/ 138955709788922656